type 1 (HTLV-I)' is responsible for adult T-cell leukemia (An)'" and is associated with the neurologic disease tropical spastic paraparesis (TSP)6. The antibody response to HTLV-1 antigens can be used for the diagnosis of the seropositive s t a t~s .~ It is also likely that an ongoing immune response (humoral andor cellular) may be responsible for the slow progression of the associated diseases,' or, if properly driven by means of vaccination, it may induce a protective response. ' Neutralizing antibodies and cytotoxic cells are the chief effector mechanisms at work during viral infection^.^"^ In both cases, Th cells'3 are required for clonal expansion of antibody-secreting B cells and of specific cytotoxic cells.'4 Therefore, the identification of Th cells specific for HTLV-1 in the human repertoire is important for the design of candidate vaccines' that include viral T-helper epitopes. Furthermore, they are useful for the identification of viral antigens that can be used as in vitro probes to test for the presence of HTLV-1 envelope-specific cellular immunity. As shown in the human immunodeficiency virus (HIV) system," this may be an additional diagnostic tool in seronegative high-risk individuals.
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MATERIALS AND METHODS
Antigens and media.
The recombinant fragments of HTLV-I envelope were purchased from Repligen (Cambridge, MA). They were expressed in Esherichia coli and contained amino and carboxy tails of E coli origin of IO to 30 residues. Sequences are based on published data for HTLV-l envelope.'6 Fragment RE1 included residues 26-200, fragment RE3 residues 166-307, fragment RE5 residues 308-401, and fragment RE6 residues 166-401. The preparation and purification of the envelope glycoprotein produced in the baculovirus expression system has been described in detail." A panel of synthetic peptides (20-mers overlapping by 10 residues) was produced by P. Neri (University of Siena, Siena, Italy). Figure 1 illustrates the boundaries of the recombinant antigens used in this study.
RPM1 1640 medium (How, Irvine, UK) was used for the generation and the maintenance of the lines and for proliferation assays.
It was supplemented with 10 mmollL L-glutamine, 0.05 mmom 2-mercaptoethanol, and 5% autologous heparinized plasma. Human ments and vice versa. The lines specific for RE and env were mapped with overlapping peptides. The lines with single peptide (narrow) specificity contained a variety of clones that used different T-cell receptor VP genes. These data (1) suggest that most of the normal individuals carry T-helper precursors specific for epitopes on HTLV-1 envelope; (2) indicate that heterogeneity of HTLV-1 envelope-specific T cells can be detected in the naive repertoire; and (3) define optimal antigenic preparations to be used to assess cellular immunity in HTLV-l-infected individuals.
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recombinant interleukin-2 (IL-2), kindly donated by R. Della Bitta (EuroCetus, Amsterdam-Milan, Italy) was used at a final concentration of 30 U/mL.
Generation of T-cell lines specijic for HTLV-1 envelope. T-cell lines were obtained by a basic protocol previously described in detai1'8-20 from HTLV-I -naive (nonimmunized and noninfected) individuals who did not belong in categories at risk because of sexual behavior or previous blood transfusions. Briefly, heparinized venous blood was separated on a Ficoll gradient to obtain peripheral blood mononuclear cells (PBMCs). PBMCs were pulsed with antigens at 1 pg/mL at a concentration of IO' cells/mL for 4 hours at 37°C. The cells were subsequently diluted to 2 X IOh/mL and 2 mL cell suspension was seeded in a 24-we11 plate (Costar, Cambridge, MA). Five days later, IL-2 was added and the cells were split when confluent. The cells were expanded with IL-2 for 10 to 14 days and restimulated with antigen-pulsed, 2,500-rad irradiated autologous PBMCs and IL-2 for two to three cycles to obtain established T-cell lines. Previous experiments (data not shown) have shown that, after four stimulation cycles, only antigen-specific T cells are present in the bulk cultures, because all of the clones generated at this stage with a mitogenic stimulus respond to the relevant antigen. Estimate of specific precursor frequency. Because of the limited number of cells available from the same donors repeatedly bled for the experiments and the lack of primary proliferative response, formal limiting dilution assay" could not be performed to determine the frequency of RE and of envelope-specific cells in PBMCs. In addition, because of the low precursor frequency, we could not use conventional frequency analysis in which the highest cell concentration yields 100% positive wells; in fact, greater than 10' cells per well should be plated, but this results in overcrowding and no positive wells could be detected in preliminary assays. Thus, we used an alternative analysis to estimate precursor frequency. Positive signals were enhanced in a two-step assay. In the first step, 24 wells of a microtiter plate were seeded with 10' antigen-pulsed PBMCs and IL-2 was added 5 days later. In the second step on day 15, each well was split into three round-bottom wells, one to maintain the clones for further expansion and the others to test specific proliferative response with or without antigen, in the presence of 5 X 10' irradiated autologous PBMCs. These wells were pulsed on day 3, harvested after 16 hours, and processed as described. Stimulation indexes (SI; cpm with antigerdcpm without antigen) ranged from 1 to 9. Wells with an SI greater than 2 were scored as positive. In fact, we have previously established that specific clones can be further expanded from the well with an SI greater than 2. This assay, although not as accurate as formal limiting dilution analysis:' allows us to estimate the relative frequency of naive precursors specific for HTLV-l antigens versus precursors specific for recall antigens such as tetanus toxoid (TT) and purified protein derivative (PPD), as described below.
RNAse protection assay. RNA preparation from T cells, riboprobe design, labeling, and the RNAse protection assay have been described in detail.2z Thirty Vp riboprobes in three probe sets were used. Probe set A was Vp 22. 6.4, 13.2, 3.1, 1.1, and 7.1. Probe set C was Vp 2.lb, 13.3, 8.3, 13.1, 6.5, 12.la, 5.5, 2.la, 12.lb, and 5.4. All sets were according to the nomenclature reported in Wilson et alZ3 and Plaza et Briefly, total cellular RNA was hybridized overnight at 56°C with C p probe or with each 32P-radiolabeled probe set. Unhybridized probes were digested with RNAse and protected probeRNA duplexes were purified, electrophoresed on a 6% polyacrylamide sequencing gel, and autoradiographed. The protected hybridized probes of defined length were identified on the film, thereby permitting definition of Vp gene usage by the T-cell lines.
T-cell receptor (TCR) Vpanalysis by polymerase chain reaction (PCR).
Analysis of TCR Vp gene segment usage by specific Tcell lines was performed by PCR on reverse transcribed cDNA by using a panel of oligonucleotide primers and following the procedure described in detail."
RESULTS
T-cell lines specz9c f o r RE fragments.
T-cell lines specific for one or more RE fragments were obtained from seven of eight individuals. A specific response can be detected by the second or third restimulation cycle (data not shown) and by the fourth or fifth cycle the lines are established. Figure 2 summarizes the lines generated from different donors. The lines were tested after four cycles. Four of seven donors gave rise to REl-specific lines, six of seven to RE3-specific lines, six of seven to RES-specific lines, and three of seven to RE6-specific lines.
The lines are specific for the fragments used for in vitro immunization, and no recognition of the E coli sequences shared by the different recombinant fragments that flank the HTLV-1 sequences can be detected. In fact, a representative T-cell line raised against fragment RE1 does not proliferate to RE3 and RES (sharing the same E coli sequences with REl), but proliferates to RE6 that overlaps with RE1 from residues 165 to 200 (Fig 3) . The lack of response to fragment RE3, which overlaps with RE1 from aa 165 to 200 as RE6, is hard to explain. This fragment has no toxic activity in that RE3-specific lines can be generated from certain donors ( Fig  2) and it has no inhibitory activity when coadministered with stimulatory fragments R E 1 and RE6 (Fig 3) .
The fine specificity of two lines derived from the same T-cell line from donor AF generated by in vitro immunization with RE1 fragment. The line induced with fragment RE1 was tested against the other recombinant fragments after the fourth cycle. Cross-response was only seen with RE6, which overlaps with RE1 by 35 amino acids (residues 165-200). The same overlapping sequence is present on peptide fragment RE3, which is nonstimulatory. Fragment RE5 does not stimulate, even though it carries the same E coliamino terminal tail of REl, thus confirming that no recognition of the flanking E coli sequences occurs.
with the envelope glycoprotein in particulate or soluble form from 9 of 10 individuals. Figure 4 shows two representative lines generated from individual FM by using particulate or soluble antigen that respond to the envelope glycoprotein independently of the particulate or soluble form. Peptide mapping showed specificity for the overlapping peptides 201-220 and 21 1-230 in both lines, suggesting that the response to this in vitro-defined imrnunodominant region is a constant feature in lines generated independently from the same individual against the same antigen in two different forms. An early response to the recombinant REI fragment was detected at the third cycle in the line induced with soluble antigen (data not shown), but it was lost at the fourth stimulation cycle, in apparent association with a restriction in clonal heterogeneity (see below). Figure 4 also shows a line generated from donor LO that responds to fragment RE1 and recognized two nonoverlapping peptides, 91-1 10 and Estimate of precursor frequency. The frequency of Tcell precursors specific for individual RE fragments was estimated in individual DF (Fig 5A) . The frequencies range from 1 to 2/106 unfractionated PBMCs. In the case of envelope-specific precursors (donors FM, DF, and GB; Fig 5B) , frequencies are in the same range. These low frequencies support the notion that the lines have been generated from donors that are HTLV-l naive to the best of our knowledge. By comparison, the frequency of TT-and PPD-specific proliferating cells detected in the same donors reflects the mem-
141-160.
For Clonal heterogeneity of HTLV-1 envelope-speciJic T cells. Keeping in mind that recognition of one single peptide does not imply T-cell monoclonality,26 two T-cell lines from donor AF specific for fragments RE1 (overlapping sequence 171-180) and RE6 (peptide 311-330) were analyzed for use of TCR Vp gene families. An RNAse protection assay was used on mRNA extracted from the T-cell lines.22 Figure 6 shows the Vp gene families that were used by the two Tcell lines specific for the recombinant RE fragments. The REl-specific line includes 1 l major Vp families. In the case of the RE6-specific line, six major Vp families were used. These results, summarized in Table 1 , indicate the presence of a large cohort of clonotypes engaged in the response to narrow regions of RE recombinant fragments. A PCR assay was also used to follow-up clonal heterogeneity of T-cell lines responsive to peptides 201-220 and 21 1-230 (21 1-220 overlap) of the envelope glycoprotein. A discrete number of TCR Vp gene families was used by the bulk line, with a loss of certain TCR Vp families after repeated stimulation cycles ( Table 2 ). The association of reduction in clonal heterogeneity and loss of responsiveness to recombinant RE fragments may be coincidental, or some RE responsive clones may belong to the V/3 families that were eventually lost in the bulk culture.
To further define clonal heterogeneity of the same T-cell lines specific for envelope, clones were obtained by limiting dilution and individually examined by PCR to define their VD gene usage. All of the clones exhibited the same peptide specificity as the bulk lines from which they were derived. Table 3 shows that most of the clones are monoclonal in nature, whereas 4 of 14 (28%) are not monoclonal, in agreement with the expected theoretical frequency of 25% according to Poisson distribution when limiting dilution is performed at 0.5 cells/well.21
DISCUSSION
Antibodies7 and cytotoxic ~e l l s~~.~~ specific for HTLV-l have been detected in infected patients. In addition, extensive information is available on B epitopes defined on envelope glycoprotein with MoAbs and with polyclonal antibodiesz9 Our focus in HTLV-I-specific human T-helper cells stems from the fact that both antibody production and induction of cytotoxic cells are dependent on specific CD4 cell^.'^,'^ The goals of our study were (1) to show the presence of specific T-helper cells in the naive repertoire of seronegative individuals not belonging to categories at risk of exposure to HTLV-1; (2) to test their fine peptide specificity; (3) to estimate the frequency of HTLV-l envelope-specific precursors in the human naive repertoire; (4) to define the clonal heterogeneity of the human primary response in vitro; and (5) to use the T-cell lines and clones as cellular reagents to define recombinant products as appropriate antigens for proliferative assays to test cellular immunity in HTLV-1-positive individuals.
The frequency of Th cell precursor specific for HTLV-1 envelope or recombinant fragments in the naive repertoire is far too low for detection by a conventional proliferation assay, as seen in the case of HIV antigens,'* but the relevant cells can be expanded in vitro by repeated stimulation with various antigenic preparations." Specific precursors are present in the repertoire of seronegative individuals, and numerous different clonotypes can recognize the retroviral antigens. The estimated frequency matches with the observed frequencies for other primary retroviral antigens (gp120 and p66 of HIV), as opposed to much higher frequencies for the conventional recall antigens tested here. In addition, because the seronegative donors used for this study do not belong to categories at risk (because of sexual practices or blood transfusion) and belong to a geographical region in which the incidence of HTLV-l seropositivity is negligible (thus ruling out also in utero exposure), these can be considered bona $de primary in vitro responses. T-cell response to the four RE fragments by donor DF. PBMCs were pulsed with the relevant fragment plated a t 106/well in 24 wells, as described in the Materials and Methods. After splitting and specific restimulation, the wells were pulsed, harvested and counted. SI greater than 2 was scored as positive. Background proliferation for the individual wells in the absence of antigen ranged from 100 to 500 cpm. The estimated precursor frequencies of specific cells in 10' PBMCs were 1.5,1.0,1.9, and 1.7 for the four RE fragments. (B) T-cell response to soluble envelope by donors FM, DF, and GB. The estimated frequencies were 2.2,1.8, and 1.4, respectively. To estimate the frequency of cells specific for recall antigens, PBMCI were plated after pulsing with TT (5 pg/mL) or with PPD (25 pg/mL) at 2 x 104/well in 24 wells (data not shown). Donor DF had a frequency of 37 TT-specific and 22 PPD-specific cells in lo* PBMCs. Frequencies for donors FV and GB were 24 and 16 and 48 and 26, respectively.
With respect to specificity, the T-cell lines we have obtained seem to discriminate the molecular context of the relevant epitopes. Data not shown here because they confirm previous findings with other retroviral antigen~l~~'~" indicate that, within the naive human repertoire, it is possible to trigger T-helper cells that recognize synthetic peptides, but not whole proteins that contain the same sequence. These are examples of T cells specific for "cryptic" epitope~.~' It is likely that, if such clones are recruited in vivo by peptidecontaining vaccines;' they may be of little relevance because of their inability to recognize the same epitope in the context of the whole protein antigen or in the context of the whole virion.
This observation confirms our previous findings in an animal model in which T-cell clones were able to discriminate between native/denatured and intact/fragmented antigen3' and with human clones specific for HIV epitopes displayed on peptides, proteins, and viral particle^.'^"
If discrimination between the various physical forms of a T-cell epitope depends also on antigen processing, in addition to a role for flanking amino acid sequences and for carbohydrate hai ins,''^"^^'-^^ and for fine specificity of T cells, it may be useful to drive processing mechanisms onto highly efficient presenting cells35 to facilitate presentation of the relevant epitopes independently of the antigenic context. An example of this possibility has been reported elsehere.'^" In this case, we showed that a T-cell epitope of a retroviral protein cannot be recognized by specific T cells when presented in the context of whole virions by monocytes as antigen presenting cells (APCs), but it was presented by B cells, suggesting that different APCs have different ability in handling complex antigenic structures. Therefore, driving the antigen onto optimal APC (eg, by the appropriate route of administration or by the use of appropriate adjuvants) may favor exploitation of T cells that would be otherwise neglected in a potentially protective response.
In addition, T-helper cells specific for "cryptic" epitopes3' may be a byproduct of the immune response in case antigenic fragments that become available upon processing and/or degradation activate such T cells unable to respond to the whole antigen. In this case, immunogens containing the stimulatory fragments (but not the nonstimulatory protein) can be linked to B-cell epitopes (T-B vaccine^)^' to enhance antibody production in those instances in which a high titer of preformed antibodies is desirable. rather than a delayed anamnestic response to the pathogen itself.
The different clonotypes defined according to Vp gene usage in T-cell lines with narrow peptide specificity may underestimate the real clonal heterogeneity. In fact. the weak signals in the RNAse protection assay may indicate clones present at very low frequency within the bulk line. Furthermore, antigen-specific T-cell clones exhibiting the same TCR VD gene usage may differ when the VDJ region of the TCR gene is sequenced. Expansion of specific T cells from a naive repertoire mimicks in vitro the events that take place during the first encounter in vivo between the T-helper compartment and the viral antigens. as in the case of accidental infection or of deliberate vaccination. These events include antigen administration, uptake and processing by the appropriate APCs. and presentation to specific T cells that are present at low frequency in the naive repertoire. Vaccination has been proposed for HTLV-I.X It has been pointed out that, in animal models of HTLV-I infection. the antibody response against envelope confers protection.2"-3x Because HTLV-I envelope glycoprotein is a candidate target for vaccination. it is useful to gain more information on its immunodominant T-helper epitopes. This may allow the inclusion of universal T-cell epitopes3'.'"' in recombinant or synthetic vaccines.".."" as proposed in other viral systems.
The identification of epitopes that are recognized by most of the individuals in the population (immunodominant and universal) may also suggest useful reagents to detect a previ- it is important to define antigenic preparations (whole proteins, recombinant fragments, or peptides) that are recognized by the majority of individuals in the population. The recombinant fragments RE3 and RE5 seem to qualify as such, but the envelope glycoprotein is also a primary immunogen in the majority of the individuals tested so far. With this information, the next step will be to screen the recombinant antigens and the panel of overlapping synthetic peptides by using T cells or T-cell lines and clones generated from individuals who had a previous contact with HTLV-l to define the antigens that are most frequently recognized, so as to include them in screening protocols for the definition of cellular immunity in seronegative high-risk individuals.
